CA3235259A1 - Method to detect rna biomarkers - Google Patents

Method to detect rna biomarkers Download PDF

Info

Publication number
CA3235259A1
CA3235259A1 CA3235259A CA3235259A CA3235259A1 CA 3235259 A1 CA3235259 A1 CA 3235259A1 CA 3235259 A CA3235259 A CA 3235259A CA 3235259 A CA3235259 A CA 3235259A CA 3235259 A1 CA3235259 A1 CA 3235259A1
Authority
CA
Canada
Prior art keywords
cancer
rna
expression
itf3756
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3235259A
Other languages
English (en)
French (fr)
Inventor
Gianluca Fossati
Chiara RIPAMONTI
Christian Steinkuhler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of CA3235259A1 publication Critical patent/CA3235259A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00—Nucleic acid detection characterised by assay method
    • C12Q2561/101—Taqman
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3235259A 2021-11-23 2022-11-22 Method to detect rna biomarkers Pending CA3235259A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT202100029558 2021-11-23
IT102021000029558 2021-11-23
PCT/EP2022/082762 WO2023094365A1 (en) 2021-11-23 2022-11-22 Method to detect rna biomarkers

Publications (1)

Publication Number Publication Date
CA3235259A1 true CA3235259A1 (en) 2023-06-01

Family

ID=80121649

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3235259A Pending CA3235259A1 (en) 2021-11-23 2022-11-22 Method to detect rna biomarkers

Country Status (9)

Country Link
US (1) US20250011878A1 (enExample)
EP (1) EP4437138A1 (enExample)
JP (1) JP2024543138A (enExample)
KR (1) KR20240105468A (enExample)
CN (1) CN118202068A (enExample)
AR (1) AR127708A1 (enExample)
CA (1) CA3235259A1 (enExample)
TW (1) TW202340480A (enExample)
WO (1) WO2023094365A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080842A1 (en) * 2023-10-11 2025-04-17 Dana-Farber Cancer Institute, Inc. Methods of cancer detection, prediction of response to therapy, and treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018499A2 (en) * 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
US20120176076A1 (en) 2011-01-10 2012-07-12 Carl Mansfield Methods and systems for powering auxiliary devices in photovol taic system
WO2014032899A1 (en) * 2012-08-31 2014-03-06 Novo Nordisk A/S Diagnosis and treatment of lupus nephritis
EP3084446B1 (en) * 2013-12-20 2022-12-14 Acetylon Pharmaceuticals, Inc. Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma
CA2995520A1 (en) * 2015-08-14 2017-02-23 Hendrik Jan VAN OOIJEN Assessment of nfkb cellular signaling pathway activity using mathematical modelling of target gene expression
WO2017070441A1 (en) * 2015-10-23 2017-04-27 Icahn School Of Medicine At Mount Sinai Identifying and treating cancer patients who are suitable for a targeted therapy using an hdac6 inhibitor
IT201700041723A1 (it) 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6

Also Published As

Publication number Publication date
JP2024543138A (ja) 2024-11-19
US20250011878A1 (en) 2025-01-09
WO2023094365A1 (en) 2023-06-01
TW202340480A (zh) 2023-10-16
CN118202068A (zh) 2024-06-14
KR20240105468A (ko) 2024-07-05
EP4437138A1 (en) 2024-10-02
AR127708A1 (es) 2024-02-21

Similar Documents

Publication Publication Date Title
McClure et al. Stat3 and C/EBPβ synergize to induce miR‐21 and miR‐181b expression during sepsis
JP6212107B2 (ja) 脱毛障害を処置するための方法
Wang et al. Expression patterns of miR-146a and miR-146b in mastitis infected dairy cattle
Harvey et al. Modulation of chemotherapeutic drug resistance in neuroblastoma SK‐N‐AS cells by the neural apoptosis inhibitory protein and mi R‐520f
Kim et al. Regulation of breast cancer-induced osteoclastogenesis by MacroH2A1. 2 involving EZH2-mediated H3K27me3
Lochhead et al. MicroRNA expression shows inflammatory dysregulation and tumor‐like proliferative responses in joints of patients with postinfectious Lyme arthritis
Zurawek et al. Time-dependent miR-16 serum fluctuations together with reciprocal changes in the expression level of miR-16 in mesocortical circuit contribute to stress resilient phenotype in chronic mild stress–an animal model of depression
Chen et al. MiR‐183 regulates ITGB1P expression and promotes invasion of endometrial stromal cells
Li et al. Identification of circ-FAM169A sponges miR-583 involved in the regulation of intervertebral disc degeneration
Janus et al. Pro-inflammatory cytokine and high doses of ionizing radiation have similar effects on the expression of NF-kappaB-dependent genes
Verma et al. Leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction induces a novel genetic signature resulting in T-cells refractory to transforming growth factor-β signaling
Kimani et al. Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase
Lu et al. Human RNase3 immune modulation by catalytic-dependent and independent modes in a macrophage-cell line infection model
US20100279296A1 (en) Enhanced fc receptor-mediated tumor necrosis factor superfamily mrna expression in peripheral blood leukocytes in patients with rheumatoid arthritis
Cobo et al. Particle uptake by macrophages triggers bifurcated transcriptional pathways that differentially regulate inflammation and lysosomal gene expression
Yuan et al. Time-series expression profile analysis of fracture healing in young and old mice
US20250011878A1 (en) Method to detect rna biomarkers
Qin et al. The long non-coding RNA OTX2-AS1 promotes tumor growth and predicts response to BCL-2 inhibition in medulloblastoma
Gu et al. Identifying hedgehog signaling specific microRNAs in glioblastomas
Wu et al. MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11
US20200318193A1 (en) Method for determining decrease in functions of hippocampus by using correlation between micro rna and nmda receptor, method for inhibiting decrease in functions, and method for screening for inhibitors of decrease in functions
Mihalas et al. KAT5 regulates neurodevelopmental states associated with G0-like populations in glioblastoma
Jiang et al. Spliceosome inhibition induces Z-RNA and ZBP1-driven cell death in small cell lung cancer
Liu et al. Identification of dysregulated microRNAs in glioma using RNA-sequencing
Zhao et al. LncRNA H19 facilitates polarization of M1 phenotype macrophages via miR-145-5p/PAI-1 axis in mediating systemic lupus erythematosus

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241115

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241115